

03-01-2002

Form PTO-1595

(Rev. 03/01)

RECOF

J.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

OMB No. 0651-0027 (exp. 5/31/2002)

101997805

Tab settings

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Inex Pharmaceuticals Corp.

2-12-02

2. Name and address of receiving party(ies)

Name: University of British Columbia

Internal Address: _____

University Industry Liaison Office

Street Address: 2194 Health Sciences Office

City: Vancouver State: BC Zip: CANADA

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:



Assignment



Merger



Security Agreement



Change of Name



Other _____

Execution Date: 12/05/01

Additional name(s) & address(es) attached? ☒ Yes ☐ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s) 08/856,374,

09/078,954, 09/078,955, 09/649,527

09/654,373

B. Patent No.(s) _____

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Marina T. Larson, PhD

Internal Address: Oppedahl & Larson LLP

Street Address: P.O. Box 5068

City: Dillon State: CO Zip: 80435

6. Total number of applications and patents involved: 5

7. Total fee (37 CFR 3.41).....\$ 200.00



Enclosed

PTO Form-2038



Authorized to be charged to deposit account

8. Deposit account number:

15-0610

DO NOT USE THIS SPACE

9. Signature.

Marina T. Larson, PhD

Name of Person Signing

Signature

January 10, 2002

Date

Total number of pages including cover sheet, attachments, and documents: 3

03/01/2002 LNUELLER 00000046 08856374

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

01 FC:501

200.00 00

PATENT
REEL: 012614 FRAME: 0671

ASSIGNMENT

WHEREAS, INEX PHARMACEUTICALS CORP., hereinafter referred to as "Assignor", is the owner by Assignment of the following US Patent Applications and convention counterparts thereof, hereinafter referred to as "Applications" :

High Efficiency Encapsulation of Antisense or Ribozymes in Lipid Vesicles, Serial No. 08/856,374;

High ratio Antisense Formulations in Lipid Carriers, Serial No. 09/078,954;

Method for Administration of Antisense Compositions With Repeat Dosing, Serial No. 09/078,955;

Compositions for Stimulating Cytokine Secretion and Inducing an Immune Response, Serial No. 09/649,527;

Novel Small Multilamellar Vesicle Structures, Serial No. 09/654,373,

and of the inventions disclosed therein;

WHEREAS, the University of British Columbia., a non-profit corporation organized and existing under the laws of Canada is desirous of acquiring the entire right, title and interest in and to said inventions and any improvements thereon, and in and to said applications for Letters Patent therefor, and any Letters Patent which may be obtained therefor;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, BE IT KNOWN, that the said Assignor, for and in consideration of the sum of One Canadian Dollar (CA\$1.00), lawful money of Canada, to it in hand paid by said University of British Columbia., and other valuable considerations unto us moving from said University of British Columbia, at or before the ensealing and delivery of these presents, the receipt of which is hereby acknowledged, have sold, assigned, transferred and conveyed and by these presents do sell, assign, transfer and convey, unto said University of British Columbia., its successors and assigns, the entire right, title and interest in and to said invention for which Inex Pharmaceuticals Corp. has made application for Letters Patent of the United States by the Applications, and any and all improvements thereon, and in and to said Applications and any division, continuation or continuation-in-part thereof, and in and to any Letters Patent of the United States which may be issued on any of said applications, and any reissues thereof, and in and to any and all applications for Letters Patent filed in foreign countries for said invention or improvements including all priority rights, and any and all


Letters patent which may be granted in foreign countries therefor, TO HAVE AND TO HOLD THE SAME to the full end of the term or terms for which any and all said Letters Patent may be granted;

AND the said Assignor, does hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent of the United States to said University of British Columbia. as the assignee of the entire right, title and interest in and to the same, for the sole use and benefit of said University of British Columbia, its successors and assigns;

AND the said Assignor, for the considerations aforesaid, does hereby covenant and agree to and with said University of British Columbia, its successors and assigns, that it has the full power to make this assignment, and that the rights assigned are not encumbered by any grant, license or right heretofore given, and that our executors or administrators, shall and will do all lawful acts and things and make, execute and deliver without further compensation, any and all other instruments in writing, further applications, papers, affidavits, powers of attorney, assignments and other documents which, in the opinion of counsel for said University of British Columbia, its successors and assigns, may be required or necessary more effectively to secure to and vest in said University of British Columbia, its successors and assigns, the entire right, title and interest in and to said invention and improvements, applications, Letters Patent, rights, titles, benefits, privileges, and advantages hereby sold, assigned, transferred and conveyed, and that Assignor will sign any applications for reissue which may be desired by the owner of the patent or patents which may be issued for the said invention or improvements.

IN WITNESS WHEREOF Inex Pharmaceuticals Corp. has hereunto set its hand and seal on the date written below.

INEX PHARMACEUTICALS CORP.

By 
Name: DAVID R. SMITH
Title: PRESIDENT + CEO
Date: Dec 5, 2001

James M. Dougall, Dec 5, 2001
Steve Galtier
Witnesses